Statutory Rules 1991 No.4421
–––––––
Health Insurance (1992 Pathology Services Table) Regulations2
I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.
Dated 12 December 1991.
BILL HAYDEN
Governor-General
By His Excellency’s Command,
B.HOWE
Minister of State for Health, Housing and Community Services
–––––––––
Citation
1. These Regulations may be cited as the Health Insurance (1992 Pathology Services Table) Regulations.
Commencement
2. These Regulations commence on 1 February 1992.
Repeal
3. Statutory Rule 1991 No. 353 is repealed.
Pathology services table
4. The table of pathology services in the Schedule is prescribed for the purposes of subsection 4a (2) of the Health Insurance Act 1973.
SCHEDULE Regulation 4
TABLE OF PATHOLOGY SERVICES
RULES OF INTERPRETATION
1. (1) In this table, unless the contrary intention appears:
“patient episode” means a pathology service, or pathology services whether listed in 1 or more items, for a single patient whose need for which was determined under subsection 16a (1) of the Act on the same day, whether rendered by 1 or more approved pathology practitioners on 1 or more days;
“recognised pathologist” means a medical practitioner recognised as a specialist in pathology under a determination under subsection 61 (3) of the Act;
“the Act” means the Health Insurance Act 1973.
(2) In these Rules, a reference to a request to an approved pathology practitioner includes a reference to a request for a pathologist-determinable service to which subsection 16a (6) of the Act applies.
2. (1) If a service is described:
(a) in an item in general terms; and
(b) in another item in specific terms;
only the item that describes the service in specific terms applies to the service.
(2) If:
(a) a service is described in 2 or more items; and
(b) subrule (1) does not apply;
only the item that provides the lower or lowest fee for the service applies to the service.
3. (1) In subrule (2), “service” includes an assay, estimation and test
(2) 2 or more pathology services rendered for a patient following 2 or more requests are taken to have been rendered following a single request if:
(a) the services are listed in the same item; and
(b) the patient’s need for die services was determined under subsection 16a (1) of the Act on the same day even if they are rendered by an approved pathology practitioner on more than one day.
4. If:
(a) a pathology service to which an item of the table applies is rendered for a patient in accordance with a request; and
(b) another pathology service is rendered for the patient in accord the request; and
(c) an item of the table:
(i) applies to the other service; and
(ii) is referred to in the item mentioned in paragraph (a);
the other service is treated as if it were part of the service referred to in paragraph (a).
Example:
Dr Proctor requests an extended blood grouping test (covered by item 65019) and the test includes a basic blood grouping test (covered by item 65017). Item 65017 is referred to in item 65019. Benefit is payable under item 65019 for the extended blood grouping test but benefit is not payable separately under item 65017 for the basic blood grouping test
5. For the purposes of items 65001 to 66200 (inclusive):
(a) if pathology services of a kind referred to in item 65017, 65018, 65019 or 65020 are rendered for a patient during a period when the patient is in hospital, the item applies only to the first pathology service of that kind rendered for the patient during that period; and
(b) tests (except the tests mentioned in items 65023 and 65024) carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request is made within 14 days of that previous patient episode.
6. For the purposes of items 66201 to 69200 (inclusive):
(a) if a pathology service involving the measurement of a substance in urine requires a 24 hour urine collection, or calculation of a substance/ creatinine ratio, the service is treated as including any estimation of creatinine in other fluids necessary for the calculation; and
(b) tests earned out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request is made within 14 days of that previous patient episode.
7. For the purposes of items 69201 to 71000 (inclusive):
(a) “serial examinations or cultures” means examinations or cultures requested on 1 occasion whether or not:
(i) the materials are received on different days by the approved pathology practitioner, or
(ii) the examinations or cultures were requested on 1 or more request forms by the treating practitioner; and
(b) tests carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.
8. For the purposes of items 71001 to 72800 (inclusive):
(a) in items 71025, 71026, 71027, 71028, 71029, 71030, 71031 and 71032, the estimation of a single antibody includes qualitative and quantitative assays for that antibody; and
(b) tests carried out on material stored from a previous patient episode in response to a later request are treated as part of that previous patient episode if the second request occurs within 14 days of that previous patient episode.
9. For the purposes of items 72801 to 73040 (inclusive):
(a) “biopsy material” means all tissue received by the approved pathology practitioner from an operation, or a group of operations, performed on a patient at the same time, other than a bone marrow biopsy; and
(b) if:
(i) a pathology service that is the examination of biopsy material is rendered under any of those items; and
(ii) a further pathology service mentioned in any of those items is also rendered using that biopsy material;
those pathology services are treated as 1 pathology service.
10. For the purposes of items 73041 to 73280 (inclusive), “serial examinations” means examinations requested on 1 occasion whether or not:
(a) the materials are received on different days by the approved pathology practitioner; or
(b) the examinations were requested on 1 or more request forms by the treating practitioner.
11. (1) For the purposes of this rule and items 73901 to 73921 (inclusive):
“approved pathology authority has the same meaning as in Division 4a of Part IIA of the Act;
“institution” means a place (other than a hospital, a nursing home or accommodation for aged persons that is attached to a nursing home or situated within a nursing home complex) at which residential accommodation or day care is, or both residential accommodation and day care are, made available to:
(a) disadvantaged children; or
(b) juvenile offenders; or
(c) aged persons; or
(d) chronically ill psychiatric patients; or
(e) homeless persons; or
(f) unemployed persons; or
(g) persons suffering from alcoholism; or
(h) persons addicted to drugs; or
(i) physically or mentally handicapped persons.
“licensed collection centre” has the same meaning as in Part IIA of the Act;
“prescribed laboratory” means a laboratory operated by:
(a) the Commonwealth; or
(b) a State; or
(c) an authority of a State or Territory; or
(d) the Northern Territory; or
(e) the Australian Capital Territory; or
(f) an Australian tertiary education institution.
“specimen collection centre” has the same meaning as in Part IIA of the Act;
“temporary collection centre” has the same meaning as in Part IIA of the Act;
“treating practitioner” has the same meaning as in paragraph 16a (1) (a) of the Act.
(2) A service mentioned in items 73901 to 73921 (inclusive) applies to a pathology service when rendered by, or on behalf of, an approved pathology practitioner who is a recognised pathologist unless:
(a) the service is rendered upon a request made in the course of an outpatient service at a recognised hospital; or
(b) the service is rendered upon a request made for a patient who is a private patient in a recognised hospital when the request was made; or
(c) the pathology equipment of a recognised hospital, or prescribed laboratory, is used in rendering the service; or
(d) a member of the staff of a recognised hospital, or prescribed laboratory, participates in the service in the course of the member’s employment with the hospital or laboratory.
(3) A service mentioned in items 73901 to 73921 (inclusive) does not apply to a pathology service to which subsection 16A (7) of the Act applies.
(4) If one item of items 73901 to 73917 (inclusive) applies to a patient episode, none of the remainder of those items apply to that patient episode.
(5) Item 73921:
(a) applies only to the approved pathology practitioner or approved pathology authority to whom the specimen mentioned in the item was referred; and
(b) applies to a service even if any item in items 73901 to 73917 (inclusive) also applies to the service.
12. The abbreviations at the end of the table may be used to identify particular pathology services or groups of pathology services.
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| | GROUP PI - HAEMATOLOGY | |
| 65001 | Blood count consisting of erythrocyte count, C-reactive protein, erythrocyte sedimentation rate, blood viscosity, haematocrit, haemoglobin, platelet count, leucocyte count, reticulocyte count - one or two procedures | 5.40 |
| 65003 | Three or more procedures to which item 65001 applies, including any calculation or measurement of erythrocyte or other indices | 7.40 |
| 65005 | Examination of blood film, with or without five part differential cell count, or five part differential cell count with or without examination of blood film, and if performed, any of these additional services -Direct Coombs test, tests for heterophile antibodies, cold agglutinins, examination of blood film by special stains to demonstrate Heinz bodies, parasites or iron, or examination of a blood film with alpha-naphthyl acetate esterase, choloroacetate esterase, neutrophil alkaline phosphotase, nitro blue tetrazolium, periodic acid Schiff, Sudan Black stains, or Kleihauer test for HbF on blood film, including any services specified in item 65027 | 9.70 |
| 65007 | Full blood examination consisting of items 65003 and 65005 | 16.40 |
| 65009 | Erythrocytes, qualitative or quantitative assessment of haemolysis or metabolic enzymes by - erythrocyte autohaemolysis test, erythrocyte fragility test, sugar water test, erythrocyte metabolic enzyme test, heat denaturation test, isopropanol precipitation test, acid haemolysis test, and quantitation of muramidase in serum or urine - one or more procedures | 22.50 |
| 65011 | Tests for the diagnosis of haemoglobinopathy consisting of haemoglobin electrophoresis and two of the following - examination for HbH, quantitation of HbA2 or HbF, including any services specified in items 65001, 65003, 65005 and 65007 | 35.00 |
| 65013 | Histopathological examination of sections of bone marrow trephine biopsy including where indicated, examination of marrow smears and any special stains and immuno-chemical techniques, including any services specified in items 65001, 65003, 65005, 65007 and 65015 | 108.00 |
| 65015 | Bone marrow examination of aspirated material including any special stains, immuno-chemical techniques and clot sections where necessary, including any services specified in items 65001, 65003, 65005 and 65007 | 78.00 |
| 65017 | Blood grouping, including back-grouping when performed - ABO and Rh (D antigen) | 9.50 |
| 65019 | Blood grouping - Rh phenotypes, Kell system, Duffy system, M and N factors or any other blood group system - one or more systems, including any services specified in item 65017 | 18.80 |
SCHEDULE- continued
| Item | Pathology service | Fee | |
| | | $ | |
| 65021 | Blood grouping, including back-grouping when performed, and examination of serum for Rh and other blood group antibodies, including identification and quantitative estimation of any antibodies detected, and including any services specified in items 65001, 65003, 65005 and 65007 | 35.00 | |
| 65023 | Compatibility testing, including all necessary grouping checks of patient and donor, examination for antibodies, identification and, if necessary, quantitative estimation of any antibodies detected and any services specified in items 65001, 65003, 65005, 65007, 65017 and 65021 including all testing performed on any one day | 86.00 | |
| 65025 | Examination of serum for blood group antibodies including identification and, if necessary, quantitative estimation of any antibodies detected | 15.60 | |
| 65027 | Direct Coombs test, qualitative or quantitative test for cold agglutinins, or heterophile antibodies, qualitative spectroscopic examination of blood for abnormal haemoglobins, qualitative test for red cell porphyrins and detection of metalbumin (Schumm’s test) including those services specified in items 65005 and 65007 - one or more tests | 8.60 | |
| 65029 | Skin bleeding time, coagulation time, prothrombin time, activated partial thromboplastin time, thrombin time (including test for presence of an inhibitor and serial tests for fibrinolysis), test for factor XIII deficiency, fibrinogen, or one of - fibrinogen degradation products, fibrin monomer or D-dimer - one estimation | 11.80 | |
| 65031 | Two estimations specified in item 65029 | 15.70 | |
| 65033 | Three estimations specified in item 65029 | 19.60 | |
| 65035 | Four or more estimations specified in item 65029 | 23.50 | |
| 65037 | Quantitative assay, by one or more techniques, of plasminogen, anti thrombin III, Protein C, Protein S, heparin co-factor II, Euglobulin clot lysis time and test for lupus anticoagulant - one estimation | 23.50 | |
| 65039 | Four or more estimations specified in item 65037 | 74.00 | |
| 65041 | Platelet aggregation in response to ADP, collagen, 5HT, ristocetin or similar substance - one or more estimations | 46.50 | |
| 65043 | Heparin assay, only when monitoring a patient on subcutaneous heparin or low molecular weight heparin - one or more estimations | 31.00 | |
| 65045 | Quantitative assay of Von Willebrand’s factor antigen (factor VIA related antigen), Von Willebrand’s factor (ristocetin cofactor), factor II, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, Fletcher factor, Fitzgerald factor, Passovy factor - one estimation | 31.00 | |
|
| 65047 | Two estimations as specified in item 65045 | 44.50 | |
| 65049 | Three or more estimations as specified in item 65045 | 58.00 | |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| | GROUP P2 - CHEMICAL | |
| 66201 | Quantitative estimation in serum, plasma, urine or any other body fluid, by any method except by reagent strip with or without reflectance meter or electrophoresis of - alanine amino-transferase, albumin, alkaline phosphatase, amylase, aspartate aminotransferase, bicarbonate, bilirubin (total and any fractions), calcium (total, dialysed or ionized), chloride, cholesterol, creatine kinase, creatine kinase isoenzymes (when not performed as specified in item 66245), creatinine, fructosamine, gamma glutamyl transpeptidase, globulin, glucose, lactate dehydrogenase, lipase, lithium, magnesium, phosphate, potassium, total protein, sodium, triglycerides, urate, urea - one estimation | 9.60 |
| 66203 | Two estimations specified in item 66201 | 11.60 |
| 66205 | Three estimations specified in item 66201 | 13.60 |
| 66207 | Four estimations specified in item 66201 | 15.60 |
| 66209 | Five estimations specified in item 66201 | 17.60 |
| 66211 | Six or more estimations specified in item 66201 | 19.10 |
| 66213 | Qualitative estimation by any method, except by reagent strip or dip-stick of the followingurine constituents - bilirubin, cystine (cysteine), haemoglobin, melanin (melanogen), myoglobin, porphobilinogen, porphyrins, urobilinogen or pH measurement of body fluids other than urine (excepting urine acidification test), or cryoglobulins or cryofibrinogen in plasma - one or more estimations | 9.30 |
| 66217 | Qualitative estimation by any method except by reagent strip or dipstick of the following faecal constituents - haemoglobin, porphyrins, reducing substances - each estimation, to a maximum of three estimations, taken on separate days | 6.20 |
| 66219 | Immunological detection of human haemoglobin in faeces, including any additional services specified in item 66217 - one estimation in any twenty eight day period | 11.80 |
| 66223 | Osmolality, estimation by osmometer, in serum or in urine - one or more estimations | 23.50 |
| 66225 | Quantitative estimation of blood gases including tests performed from - pO2, oxygen saturation, pCO2, bicarbonate, pH, and any other measurement (eg. haemoglobin, potassium) or calculation performed on the same specimen _ one or more estimations on one specimen | 32.00 |
| 66227 | Estimation of blood gases as specified in item 66225 on each specimen in excess of 1 to a maximum of 6 specimens within any one day | 8.40 |
| 66229 | Calculus, analysis of one or more | 29.00 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 66231 | Drug or chemical assays - including all qualitative and quantitative tests on blood, urine or other body fluid for a drug or drugs of abuse, including illegal drugs and legally available drugs taken other than in appropriate dosage, ingested or absorbed toxic chemicals including any services specified in items 66235, 66237 and 66239, but excluding the surveillance of sports people and athletes for performance improving substances - one or more assays | 39.00 |
| 66233 | Drug assays - including all qualitative and quantitative estimations on blood, urine or other body fluid for a drug or drugs of abuse or a therapeutic drug on a sample collected from a patient participating in a drug abuse treatment programme, or being treated for drug effects or under a court order or parole board supervision, but excluding the detection of nicotine and metabolites in smoking withdrawal programmes - each assay to a maximum of four assays within any twenty eight day period | 19.60 |
| 66235 | Drug assay - quantitative estimation on blood or other body fluid by any method or methods of a drug being used therapeutically for the patient from whom the specimen was taken and not elsewhere specified in the Schedule - one estimation | 19.60 |
| 66237 | Two estimations specified in item 66235 | 27.30 |
| 66239 | Three or more estimations specified in item 66235 | 35.00 |
| 66243 | Amniotic fluid, spectrophotometric examination of, estimation of lecithin/sphingomyelin ratio, palmitic acid, phosphatidylglycerol or lamellar body phospholipid - one or more examinations or estimations | 31.00 |
| 66245 | Electrophoresis, quantitative or qualitative of serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, or the isoenzymes of lactate dehydrogenase, alkaline phosphatase and creatine kinase or lipoprotein electrophoresis (only when the Cholesterol is >6.5mmol/l and Triglyceride >3.0 mmol/1 or in the diagnosis of types III and IV hyperlipidaemia), including the preliminary quantitation of total protein, albumin and globulin or of total relevant enzyme activity - one examination to a maximum of two examinations in any twelve month period | 29.00 |
| 66247 | Electrophoresis, quantitative or qualitative of concurrently collected, or collected within a twenty eight day period, serum, urine or other body fluid to demonstrate protein classes or presence and amount of paraprotein, including the preliminary quantitation of total protein, albumin and globulin, or of total relevant enzyme activity - two or more examinations | 43.00 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 66251 | Alpha-feto protein, Alpha-1 antitrypsin, Alpha-2 macroglobulin, beta-2 microglobulin, C-l esterase inhibitor, Caeruloplasmin, Ferritin (unless specified in item 66263), Haptoglobins, Microalbumin (in proven diabetes mellitus), Prealbumin, Prostate Specific Antigen, Prostatic Acid Phosphotase, Transferrin (unless specified in item 66263), and, in the follow up of proven malignancy, Mucin-like carcinoma associated antigen, CA-125 antigen, CA-19.9 antigen, CA-15.3 antigen, Carcinoembryonic antigen, Mammary serum antigen, Neuron specific enolase, Thyroglobulin - quantitative estimation in serum, urine or other body fluid - one estimation | 18.80 |
| 66253 | Two or more estimations specified in item 66251 | 35.00 |
| 66263 | Iron studies consisting of quantitative analysis of iron, transferrin or iron binding capacity and ferritin | 37.00 |
| 66265 | Serum B12, serum folate - one or more estimations within any twenty eight day period | 23.50 |
| 66267 | Red cell folate and serum B12 and, if required, serum folate, to a maximum of three estimations in any twelve month period | 42.50 |
| 66269 | Vitamins, quantitative estimation in blood, urine or other body fluid, by direct or indirect means, of Vitamins A, B1, B2, B3, B6, C, and E - one or more estimations within any six month period | 29.00 |
| 66271 | Vitamin D or D fractions - one or more estimations | 29.00 |
| 66273 | Acetoacetate, alcohol, aminoacids, ammonia, angiotensin converting enzyme, betahydroxybutyrate, cholinesterase, cystine (cysteine), total free fatty acids, histamine, hydroxyindoleacetic acid, hydroxyproline, lactate, neonatal bilirubin (one or more fractions), oxalate, pyruvate, serotonin, xylose, zinc - one quantitative estimation | 23.50 |
| 66275 | Two or more estimations specified in item 66273 | 36.50 |
| 66277 | Aluminium, arsenic, beryllium, cadium, copper, chromium, gold, manganese, mercury, nickel, selenium, strontium - in blood, urine or other body fluid or tissue - one or more estimations within any six month period | 33.00 |
| 66279 | Blood lead estimation, other than for occupational health screening purposes, to a maximum of three estimations in any six month period - each estimation | 29.00 |
| 66281 | Porphyrins (one or more fractions), Catecholamines (one or more fractions), Hydroxy Methoxy Mandelic Acid (HMMA), Homovanillic Acid (HVA), Metanephrines, Methoxy Hydroxy Phenylethylene Glycol (MHPG), Phenyl Acetic Acid (PAA) - quantitative including any qualitative estimations - one or more estimations | 37.50 |
| 66283 | Faecal fat, Breath Hydrogen measurements in response to loading with disaccharides - one or more quantitative estimations within any twenty eight day period | 37.50 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 66285 | Solid tissue or tissues excluding blood elements - assay of one or two enzymes | 37.50 |
| 66287 | Assay of three to five enzymes as specified in item 66285 | 70.00 |
| 66289 | Assay of six or more enzymes as specified in item 66285 | 93.00 |
| 66291 | Thyroid function tests, including thyrotrophin (TSH) and at least one or more of the following tests - free thyroxine index, free thyroxine, free T3, total T3, thyroxine binding globulin | 39.00 |
| 66293 | Thyrotrophin releasing hormone (TRH) test, including provision and administration of TRH and all necessary estimations of hormones | 46.50 |
| 66295 | Growth hormone suppression by glucose loading, Growth hormone stimulation by exercise, Dexamethasone suppression test, L-Dopa stimulation of growth hormone, where physically performed by a recognised pathologist - one or more procedures | 11.00 |
| 66297 | Gonadotrophin releasing hormone stimulation test, Synacthen stimulation test, Glucagon stimulation test with C-peptide measurement, Pentagastrin stimulation of thyrocalcitonin release, Secretin stimulation of gastrin release, Insulin hypoglycaemia, Arginine infusion, where physically performed by a recognised pathologist - one procedure | 37.00 |
| 66299 | Two or more tests specified in item 66297 | 59.00 |
| 66301 | Hormones and hormone binding proteins, quantitative estimation by any method of - ACTH, Aldosterone, Androstenedione, C-peptide, Calcitonin, .Cortisol, Cyclic AMP, DHEAS, 11-Deoxycortisol, Dihydrotestosterone, FSH, Gastrin, Glucagon, Growth hormone, Human Placental Lactogen, Hydroxyprogesterone, Insulin, LH, Oestradiol, Oestriol, Oestrone, Progesterone, Prolactin, PTH, Renin, Sex hormone binding globulin, Somatomedin C(IgF1), free or total Testosterone, TSH (where not requested as part of a thyroid function test), Urine steroid fraction or fractions, Vasoactive intestinal peptide, Vasopressin (anti diuretic hormone) - one estimation | 30.00 |
| 66303 | Two estimations specified in item 66301 | 40.60 |
| 66305 | Three estimations specified in item 66301 | 51.20 |
| 66307 | Four estimations specified in item 66301 | 61.80 |
| 66309 | Five estimations specified in item 66301 | 72.40 |
| 66311 | Six or more estimations specified in item 66301 | 83.00 |
| 66315 | Hormone receptor assay on proven primary breast or ovarian carcinoma or a metastasis from a breast or ovarian carcinoma or a subsequent lesion in the breast - one or more assays | 76.00 |
| 66317 | HDL cholesterol, or apolipoprotein B/A1 ratio, estimation of, in patients with serum cholesterol >5.5mmol/l or those on prescribed lipid lowering drugs - each estimation to a maximum of four estimations in any twelve month period | 11.80 |
SCHEDULE- continued
| Item | Pathology service | Fee | |
| | | $ | |
| 66319 | Glycosylated haemoglobin only when performed in the management of established diabetes - each estimation to a maximum of four estimations in any twelve month period | 15.80 | |
| GROUP P3 - MICROBIOLOGY | |
| 69201 | Microscopic examination of material other than blood, from one or more sites, obtained directly from a patient and excluding material from cultures - wet film, inlcuding differential cell count if performed, examination for dermatophytes or dark ground illumination, or stained preparation or preparations using any relevant stain or stains - one or more examinations | 7.00 | |
|
|
|
|
| 69203 | Microscopic examination of faeces for parasites using concentration techniques including the use of appropriate stains, to a maximum of three estimations taken on separate days including any services specified in item 69201 - each estimation | 11.80 | |
|
|
|
| 69205 | The cultural examination and microscopical examination when indicated (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from nasal swabs, throat swabs, eye swabs and ear swabs, including pathogen identification and antibiotic sensitivity testing, including any services specified in items 69201 - one or more sites | 18.40 | |
|
|
|
|
|
|
| 69207 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) to determine the presence of pathogenic micro-organisms, including fungi but excluding viruses, from the following sites - skin or other superficial sites, urethra, vagina, cervix or rectum (except for faecal pathogens), or specimens of sputum (except when part of item 69213), including pathogenic identification and antibiotic sensitivity testing, including any services specified in items 69201 and 69205 - one or more examinations on one or more specimens | 27.00 | |
|
|
|
|
|
|
|
|
| 69209 | Microscopical and cultural examination (including the detection of antigens not elsewhere specified in the Schedule) of post-operative wounds, aspirations of body cavities, synovial fluid CSF and operative or biopsy specimens for the presence of pathogenic micro-organisms, including fungi but excluding viruses, involving aerobic and anaerobic culture and the use of different culture media and including pathogen identification and antibiotic sensitivity testing, including any services specified in items 69201, 69205 and 69207 - one or more sites | 36.50 | |
|
|
|
|
|
|
|
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 69211 | Cultural examination (including the detection of Clostridial toxins or antigens not elsewhere specified in the Schedule) of faeces to determine the presence or absence of faecal pathogens, involving the use of at least two selective or enrichment media as well as culture in at least two different atmospheres and includes pathogen identification and antibiotic sensitivity testing, including any services specified in item 69201, to a maximum of three specimens in any seven day period - each examination | 44.50 |
| 69213 | Microscopy with appropriate stains and cultural examinations of three specimens of sputum, urine or other bodily fluids for mycobacteria and any other bacterial pathogens, including pathogen identification and antibiotic sensitivity testing and including any services specified in item 69201 | 62.00 |
| 69215 | Blood culture to determine the presence or absence of pathogenic micro-organisms excluding viruses, including serial cultures and sub-cultures, any relevant cultural methods and any tests necessary to identify any cultured pathogen and necessary antibiotic sensitivity testing - each set of cultures to a maximum of three sets | 16.20 |
| 69217 | Urine examination including serial examination, with cell count, relevant stained preparations, cultur, colony count by any method, identification of any cultured pathogens, antibiotic sensitivity testing when necessary, and with any relevant general examination for pH, specific gravity, blood, albumin, urobilinogen, sugar, acetone or bile salts (Simple culture by dip slide is excluded from this item) | 19.00 |
| 69219 | Direct detection of the antigens of Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, Group B streptococcus (in CSF and urine specimens only), RSV, cryptococcal antigens and Varicella zoster or detection of Clostridium difficile toxin except where item 69211 has been performed - one or more estimations | 15.60 |
| 69221 | Direct detection of Chlamydia from clinical material, not cultures -one or more estimations | 9.30 |
| 69223 | Direct detection of Herpes simplex from clinical material, not cultures - one or more estimations | 9.30 |
| 69225 | Investigation for Herpes simplex virus (one or more types) or Chlamydia trachomatis, in material obtained directly from a patient, by one or more cultural methods, including any services specified in items 69221 and 69223 | 27.00 |
| 69227 | All microbiological serology during pregnancy, which must include the determination of Rubella immune status, syphilis serology and Hepatitis B surface antigen and including all services in Items 69229, 69243 and 69245, except in the investigation of a clinically apparent intercurrent microbial illness during that pregnancy | 27.00 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 69229 | Antibodies to microbial or exogenous antigens not elsewhere specified in the Schedule - estimation of one antibody | 13.30 |
| 69231 | Two estimations specified in item 69229 | 20.30 |
| 69233 | Three estimations specified in item 69229 | 27.30 |
| 69235 | Four estimations specified in item 69229 | 34.30 |
| 69237 | Five estimations specified in item 69229 | 41.30 |
| 69239 | Six or more estimations specified in item 69229 | 48.30 |
| 69243 | Hepatitis B surface antigen test | 13.20 |
| 69245 | Hepatitis B serology to define the immune status of an individual, including at least Hepatitis B surface antibody or Hepatitis B core antibody tests, including services specified in items 69243, 69247 and 69249 | 17.80 |
| 69247 | All serological tests performed for the identification of the agent causing acute Hepatitis, which must include Hepatitis B surface antigen, Hepatitis B core antibody and Hepatitis A IgM antibody tests and those services specified in items 69243, 69245 and 69249 | 35.00 |
| 69249 | All tests performed in the follow up of a patient with proven Hepatitis B, including Hepatitis B surface antigen and either Hepatitis Be antigen or Hepatitis B surface antibody tests, including services specified in items 69243 and 69245 | 25.50 |
| 69251 | Antibiotics or anti-microbial chemo-therapeutic agents, concentration in serum, urine or other body fluid, by direct quantitative measurement of the agent - one or more estimations | 23.50 |
| GROUP P4 - IMMUNOLOGY |
| 71001 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 66245, 66247 or 71005), on serum, urine or other body fluid, or examination of CSF for oligoclonal proteins by immunoelectrophoresis or immunofixation - one or more procedures | 29.00 |
| 71003 | Examination for, and identification of, a paraprotein (not previously identified), the presence of which is suggested by other tests (eg item 66245, 66247 or 71005) on serum and urine concurrently collected -two or more procedures | 43.00 |
| 71005 | Immunoglobulins G, A, M or D, quantitative estimation in serum, urine or other body fluid, by any method- estimation of one immunoelobin | 14.00 |
| 71007 | Two estimations specified in item 71005 | 21.70 |
| 71009 | Three or more estimations specified in item 71005 | 29.40 |
| 71011 | Subclasses of Immunoglobulin G, 1 to 4, estimation where there is a reduced level of clinical significance of either total IgG or IgA - one or more estimations | 43.00 |
| | | |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 71013 | Immunoglobulin E (total), quantitative estimation by any method or methods, with a maximum of two estimations in any twelve month period | 24.50 |
| 71015 | Specific IgG or IgE antibodies to potential allergens - one or more tests for single or multiple allergens with a maximum of four estimations in any twelve month period | 22.50 |
| 71017 | Antinuclear antibodies, detection in serum or other body fluids, including quantitation if required | 23.50 |
| 71019 | Measurment of DNA binding (by Farr or equivalent assay, but excluding the Crithidia method), performed only where a positive antinuclear antibody titre of 1:40 or greater has been obtained | 28.50 |
| 71021 | Antibodies to extractable nuclear antigens, detection of in serum or other body fluids | 19.60 |
| 71023 | Characterization of antibodies to extractable nuclear antigens, performed only where a positive result is obtained including services specified in item 71021 | 31.00 |
| 71025 | Antibodies to tissue antigens which are not elsewhere specified in an item in the Schedule - estimation of one antibody | 23.00 |
| 71027 | Two estimations specified in item 71025 | 27.00 |
| 71029 | Three estimations specified in item 71025 | 31.00 |
| 71031 | Four or more estimations specified in item 71025 | 35.00 |
| 71033 | Rheumatoid factor, detection of by any technique | 9.30 |
| 71035 | Quantitation of Rheumatoid factor where detected, including services specified in item 71033 | 18.40 |
| 71037 | Complement - total and components - one quantitative estimation | 15.40 |
| 71039 | Two estimations as specified in item 71037 | 23.10 |
| 71041 | Three or more estimations as specified in item 71037 | 30.80 |
| 71043 | Leucocyte fractionation as a preliminary to leucocyte marker or leucocyte function tests | 29.00 |
| 71045 | Functional tests for leucocytes, including use of all appropriate techniques (except E. rosette technique or similar) and any test specified in Group P1 - Haematology in the Schedule | 48.50 |
| 71047 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techniquesto assess lymphoid populations using a minimum of three monoclonal antibodies, including any services in item 71049 - one or more estimations | 62.00 |
| 71049 | Leucocyte surface marker characterization by immunofluorescence or immunoenzyme techiques in the investigation of a probable haematological malignancy using a minimum of seven monoclonal antibodies, including any services in item 71047 - one or more estimations | 148.00 |
| 71051 | HLA typing comprising A, B, C and DR phenotypes | 66.00 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 71053 | HLA typing, excluding any services specified in item 71051 - one or more antigens | 27.00 |
| 71055 | Mantoux test | 9.30 |
| GROUP P5 - HISTOPATHOLOGY |
| 72801 | Histopathology examination of biopsy material including all tissue processing, staining and professional opinion or opinions | 75.00 |
| 72803 | Immediate frozen section diagnosis of biopsy material, including any other histopathology examination | 122.00 |
| 72805 | Immunohistochemical investigation of biopsy material by one or more of immunofluorescent, immunoperoxidase or other labelled antibody techniques including any other histopathology examination | 93.00 |
| 72807 | Electron microscopy of biopsy material including any other histopathology examination | 99.00 |
| | GROUP P6 - CYTOPATHOLOGY | |
| 73043 | Cytological examination including serial examinations of smears from skin, nipple discharge, lip, mouth, nose or anus for detection of pre-cancerous or cancerous changes - one or more examinations | 14.40 |
| 73045 | Cytological examination including serial examinations for malignant cells of body fluids, sputum (single specimen), urine (single specimen), washings or brushings not specified in item 73043 and any histopathological service performed on that cytology specimen - one or more examinations | 28.00 |
| 73047 | Cytological examination including examination of a series of three sputum or urine specimens for malignant cells | 58.00 |
| 73049 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues | 35.00 |
| 73051 | Cytological examination of material obtained from a patient by fine needle aspiration of solid tissue or tissues where the aspiration is performed by a recognised pathologist; or where a recognised pathologist attends the aspiration and performs cytological examination during the attendance | 66.00 |
| 73053 | Routine cytological examination of smears from cervix for detection of pre-cancerous or cancerous changes in women with no symptoms, signs or recent history suggestive of cervical neoplasia and smears repeated due to an unsatisfactory routine smear - each examination | 12.00 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 73055 | Cytological examination of smears from cervix in association with the management of previously detected abnormalities including precancerous or cancerous conditions, or the investigation of women with symptoms, signs or recent history suggestive of cervical neoplasia, not associated with Item 73053 -each examination | 12.00 |
| 73057 | Cytological examination of smears from vagina, not associated with Items 73053 or 73055 - each examination | 12.00 |
| GROUP P7 - CYTOGENETICS |
| 73281 | Chromosome studies, including preparation, count and karyotyping of one or more of amniotic fluid, bone marrow, skin and any other tissue or fluid excluding blood - one or more estimations | 128.00 |
| 73283 | Chromosome studies, including preparation, count and karyotyping of blood | 116.00 |
| 73285 | Chromosome identification by banding techniques (using fluorescein, Giemsa, or centromere staining or high resolution analysis); or by fragile X-site determination - one or more identifications | 99.00 |
| GROUP P8 - INFERTILITY AND PREGNANCY TESTS |
| 73521 | Semen examination for presence of spermatozoa or examination of cervical mucus for spermatozoa (Huhner’s test) | 6.50 |
| 73523 | Semen examination, involving measurement of volume, sperm count, motility, examination of stained preparations, morphology, and, if performed, differential count and one or more chemical tests, with a maximum of four examinations in any twelve month period | 27.00 |
| 73525 | Sperm antibodies, sperm penetrating ability - one or more tests | 17.40 |
| 73527 | Chorionic gonadotrophin (beta - HCG), qualitative estimation in serum or urine by one or more methods, including serial dilution if performed, for diagnosis of pregnancy - one or more estimations | 9.50 |
| 73529 | Chorionic gonadotrophin (beta-HCG), qualitative (if performed) and quantitative estimation in serum by one or more methods for diagnosis of hydatidiform mole, HCG - secreting neoplasm, threatened abortion or follow-up of abortion | 27.00 |
| GROUP P9 - SIMPLE BASIC PATHOLOGY TESTS |
| 73801 | Seminal examination for presence of spermatozoa | 6.20 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 73802 | Blood count consisting of leucocyte count, erythrocyte sedimentation rate, examination of blood film (including differential leucocyte count) or any or all of haemoglobin estimation, haematocrit estimation or erythrocyte count - one procedure | 4.15 |
| 73803 | Two procedures specified in item 73802 | 6.20 |
| 73804 | Three or more procedures specified in item 73802 | 8.25 |
| 73805 | Microscopical examination of urine | 4.15 |
| 73806 | Pregnancy test by one or more immunochemical methods | 10.15 |
| 73807 | Microscopical examination of wet film other than urine | 6.20 |
| 73808 | Microscopical examination of gram stained film | 7.85 |
| 73809 | Chemical tests for occult blood in faeces by reagent stick, strip, tablet or similar method | 2.10 |
| 73810 | Microscopical examination screening for fungi in skin, hair or nails -one or more sites | 6.20 |
| 73811 | Mantoux test | 10.15 |
| GROUP P10 - PATIENT EPISODE INITIATION |
| 73901 | Initiation of a patient episode by collection of specimen for a service specified in item 73053, 73055 or 73057 from a person who is not in a recognised hospital or a prescribed laboratory | 7.50 |
| 73903 | Initiation of a patient episode by collection of specimen for a service specified in item 72801 from a person who is an in-patient of a hospital other than a recognised hospital | 13.50 |
| 73905 | Initiation of a patient episode by collection of specimen for a service specified in item 72801 from a person who is not an in-patient of a private hospital and not a patient of a recognised hospital | 7.50 |
| 73907 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected in a licensed collection centre other than a temporary licensed collection centre | 15.50 |
| 73909 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority from a person who is an in-patient of a hospital other than a recognised hospital | 15.50 |
SCHEDULE- continued
| Item | Pathology service | Fee |
| | | $ |
| 73911 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by an approved pathology practitioner or an employee of an approved pathology authority, from a person in the place where the person was residing or in a nursing home or institution | 15.50 |
| 73913 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905, 73907 and 73801 to 73811 (inclusive) where the specimen is collected from the person by the person | 9.50 |
| 73915 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected by or on behalf of the treating practitioner | 9.50 |
| 73917 | Patient episode initiated by collection of specimen for a service other than a service specified in items 73901, 73903, 73905 and 73801 to 73811 (inclusive) where the specimen is collected in a temporary licensed collection centre | 9.50 |
| GROUP P11 - SPECIMEN REFERRED |
| 73921 | Referral of specimen by an approved pathology practitioner of an approved pathology authority to another approved pathology practitioner of another approved pathology authority or to another approved pathology authority | 9.50 |
ABBREVIATIONS
A. ABBREVIATIONS FOR GROUPS OF TESTS
| Group | Estimations Included in Group | Abbreviation | Item Numbers |
| Cardiac Enzymes | Lactate dehydrogenase (LDH) Aspartate aminotransferase (AST) and Creatine kinase (CK) | CE | 66205/66206 |
| Coagulation Studies | Prothrombin Time, activated partial thromboplastin time and two or more of the following tests-bleeding time, thrombin clotting time, fibrinogen degradation products, fibrin monomer, D-dimer Factor XIII screening tests. | COAG | 65035/65036 |
| Electrolytes | Sodium (NA) Potassium (K) Chloride (CL) and Bicarbonate (HCO3) | E | 66207/66208 |
| Lipid Studies | Cholesterol (CHOL) and Triglycerides (TRIG) | FATS | 66203/66204 |
| Liver | Alkaline phosphatase (ALP), | LFT | 66211/66212 |
| Function | Alanine aminotransferase | | |
| Tests | (ALT), Aspartate aminotransferase (AST), Albumin (ALB), Bilirubin (BLL), Gamma glutamyl transpeptidase (GGT), Lactate dehydrogenase (LDH), and Protein (PROT). | | |
A. ABBREVIATIONS FOR GROUPS OF TESTS - continued
| Group | Estimations Included in Group | Abbreviation | Item Numbers |
| Syphilis | Rapid plasma reagin test | STS | 69231/69232 |
| Serology | (RPR) or venereal disease research laboratory test (VDRL) and Treponema pallidum haemagglutin test (TPHA) or Fluorescent Treponemal antibody-absorption test (FTA) | | |
| Urea, | Urea, | U&E | 66205/66206 |
| Electrolytes, | Electrolytes, | | |
| Creatine | Creatine | | |
| | | | |
B. ABBREVIATIONS FOR INDIVIDUAL TESTS
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Abnormal haemoglobins | AH | 65027,65028 |
| Acetoacetate | ACAT | 66273,66274 |
| Acetylated Sulphadimidine | ASUL | 66235,66236 |
| Adrenocorticotrophic hormone | ACTH | 66301,66302 |
| AFB Microscopy and culture of Sputum | AFB | 69213,69214 |
| Alanine Aminotransferase | ALT | 66201,66202 |
| Albumin | ALB | 66201,66202 |
| Alcohol (Ethanol) | ETOH | 66273,66274 |
| Aldosterone | ALD | 66301,66302 |
| Alkaline Phosphatase | ALP | 66201,66202 |
| Phosphatase Isoenzymes | ALPI | 66245,66246 |
| Alpha feto protein | AFP | 66251,66252 |
| Alpha-1 antitrypsin | A AT | 66251,66252 |
| Alpha-2 macroglobulin | AMAC | 66251,66252 |
| Aluminium | AL | 66277,66278 |
| Amiodarone | AMIO | 66235,66236 |
| Amitriptyline | AMIT | 66235,66236 |
| Ammonia | NH3 | 66273,66274 |
| Amniotic Fluid Examination | AFE | 66243,66244 |
| Amylase | AMS | 66201,66202 |
| Amylobarb | AMYL | 66235,66236 |
| Androstenedione | ANDR | 66301,66302 |
| Angiotensin converting enzyme | ACE | 66273,66274 |
| Antibiotic & antimicrobial chemotherapeutic agents, quantitative assay | | |
| QAA | 69251,69252 |
| Antibodies to | | |
| Extractable Nuclear Antigens - detection | ENA | 71021,71022 |
| Extractable Nuclear Antigens - characterization of antibodies if positive ENA | | |
| ENAP | 71023,71024 |
| Nuclear Antigens - detection | ANA | 71017,71018 |
| Nuclear Antigens-quantitation & measurement of DNA binding if positive ANA | | |
| ANAP | 71019,71020 |
| Tissue Antigens: | | |
| Acetylcholine Receptor | ARA | 71025,71026 |
| Adrenal cell | ADR | 71025,71026 |
| Cardiolipin | ACL | 71025,71026 |
| Centromere | ACA | 71025,71026 |
| Gastric parietal cell | PCA | 71025,71026 |
| Gliadin IgA | GLIA | 71025,71026 |
| Glomerular basement membrane | GBA | 71025,71026 |
| Insulin Receptor Antibodies | INSA | 71025,71026 |
| Intercellular cement substance of skin | ICCS | 71025,71026 |
| Jo-1 | JO1 | 71025,71026 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Keratin | KERA | 71025,71026 |
| Liver/Kidney microsomes | LKA | 71025,71026 |
| Mitochondria | MA | 71025,71026 |
| Parathyroid | PTHA | 71025,71026 |
| PM-1 | PM1 | 71025,71026 |
| Reticulin | RCA | 71025,71026 |
| Skeletal muscle | SLA | 71025,71026 |
| Skin basement membrane | SKA | 71025,71026 |
| Smooth muscle | SMA | 71025,71026 |
| SCL 70 | SCL | 71025,71026 |
| Thyroid Microsomal | TMA | 71025,71026 |
| TSH Receptor Antibody test | TSHA | 71025,71026 |
| Antibody Testing, Microbial | | (see Microbial) |
| Antigen Testing, Microbial | | (see Microbial) |
| Antithrombin III | ATH | 65037,65038 |
| Arginine | ARLN | 66297,66298 |
| Arsenic | AS | 66277,66278 |
| Aspartate Aminotransferase | AST | 66201,66202 |
| Barbitone | BARB | 66235,66236 |
| Beryllium | BE | 66277,66278 |
| Beta Hydroxybutyrate | BHYB | 66273,66274 |
| Beta-2 microglobulin | BMIC | 66251,66252 |
| Bicarbonate | HCO3 | 66201,66202 |
| Bilirubin (all fractions) | BILI | 66201,66202 |
| (Neonatal) | BILN | 66273,66274 |
| Bleeding Time | BT | 65029,65030 |
| Blood Culture | BC | 69215,69216 |
| Film | BF | 65005,65006 |
| Gases | GAS | 66225,66228 |
| Group and blood group antibodies | BGAB | 65021,65022 |
| Group Antibodies | BGA | 65025,65026 |
| Group Systems | BGS | 65019,65020 |
| Grouping-ABO and RH (D antigen) | BG | 65017,65018 |
| Bone Marrow Examination - Aspirate | BMEA | 65015,65016 |
| - Trephine | BMET | 65013,65014 |
| Breath Hydrogen test | BHT | 66283,66284 |
| Bromide | BRMD | 66235,66236 |
| Butobarb | BUTO | 66235,66236 |
| C-1 esterase inhibitor | CEI | 66251,66252 |
| C-Peptide | CPEP | 66301,66302 |
| C-reative protein | CRP | 65001,65002 |
| CA-125 antigen | C125 | 66251,66252 |
| CA-15.3 antigen | CA15 | 66251,66252 |
| CA-19.9 antigen | CA19 | 66251,66252 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Cadmium | CP | 66277,66278 |
| Caeruloplasmin | CPLS | 66251,66252 |
| Calcitonin | CALT | 66301,66302 |
| Calcium (total, dialysed or ionized) | CA | 66201,66202 |
| Calculus Analysis | CALC | 66229,66230 |
| Carbamazepine (Tegretol) | CARB | 66235,66236 |
| Carboxyhaemaglobin | COHB | 65027,65028 |
| Carcinoembryonic antigen | CEA | 66251,66252 |
| Catecholamines | CAT | 66281,66282 |
| Chlamydia Investigation by Cultural Methods | CHLC | 69225,69226 |
| Chloral Hydrate | CHHY | 66235,66236 |
| Chlorazepate | CHZP | 66235,66236 |
| Chloride | CL | 66201,66202 |
| Chloroquine | CLOQ | 66235,66236 |
| Chlorpromazine | CHLO | 66235,66236 |
| Cholesterol | CHOL | 66201,66202 |
| Cholinesterase | CHSE | 66273,66274 |
| Chorionic gonadotrophin for pregnancy diagnosis | HCG | 73527,73528 |
| - for diagnosis of specified conditions | HCGD | 73529,73530 |
| Chromium | CR | 66277,66278 |
| Chromosome indentiflcation by banding technique | CSI | 73285,73286 |
| studies | CS | 73281,73282 |
| studies of blood | CSB | 73283,73284 |
| Cimetidine | CMTD | 66235,66236 |
| Clobazam | CLOB | 66235,66236 |
| Clonazepam (Rivotril) | CLON | 66235,66236 |
| Clostridium difficile | CLDT | 69219,69220 |
| Coagulation factors (see individual factors) time | CT | 65029,65030 |
| Cold Agglutinins | CAG | 65027,65028 |
| Collection of specimen (s) for cytological examination | | 73053,73055, 73057,73901, 73903,73905, 73907,73909 |
| Compatibility testing | XMAT | 65023,65024 |
| Complement Total, C3 or C4 | COM | 71037,71038 |
| (Other complements must be specified) | | |
| Copper | CU | 66277,66278 |
| Cortisol | CORT | 66301,66302 |
| Creatine Kinase | CK | 66201,66202 |
| Kinase Isoenzymes | CKI | 66201,66202 |
| Kinase Isoenzymes (electrophoresis) | CKIE | 66245,66246 |
| Creatinine | C | 66201,66202 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Cryofibrinogen | CFIB | 66213,66214 |
| Cryoglobulins | CGLB | 66213,66214 |
| Cryptococcal antigen | CRYN | 69219,69220 |
| CSF antigens | | |
| - Haemophilus influenzae | CSFA | 69219,69220 |
| - Streptococcus pneumoniae | CSFA | 69219,69220 |
| - Neisseria meningitidis | CSFA | 69219,69220 |
| - Group B streptococcus | CSFA | 69219,69220 |
| Cultural Examination of Faeces | FCS | 69211,69212 |
| Cyclic AMP | CAMP | 66301,66302 |
| Cyclosporin A | CLSA | 66235,66236 |
| Cysteine (see Urine Cystine) | UCYS | 66213,66214 |
| Cystine (cysteine) | CYST | 66273,66274 |
| Cytology from body fluids, sputum (1 specimen), urine, washings or brushings | | |
| BFCY | 73045,73046 |
| - from cervix | CCR | 73053,73054, |
| | | 73055,73056 |
| - from fine needle aspiration of solid tissues | FNCY | 73049,73050 |
| - from fine needle aspiration of solid tissues aspiration or attendance by a pathologist | | |
| FNCP | 73051,73052 |
| - from skin, nipple discharge, lip, mouth, nose or anus | SMCY | 73043,73044 |
| - from vagina | CVO | 73057,73058 |
| - from 3 sputum or urine specimens | SPCY | 73047,73048 |
| D-dimer test | DD | 65029,65030 |
| Dehydroepiandrosterone sulphate | DHEA | 66301,66302 |
| Deoxycortisol | DCOR | |
| Desethyl Amiodarone | DEAM | 66235,66236 |
| Desipramine | DESI | 66235,66236 |
| Dexamethasone | DXST | 66295,66296 |
| Suppression test | DEXA | 66301,66302 |
| Diazepam | DIAZ | 66235,66236 |
| Differential Cell Count | DIFF | 65005,65006 |
| Digoxin | DIG | 66235,66236 |
| Dihydrotestosterone | DHTS | 66301,66302 |
| Diphenylhydantion (Dilantin) | DLL | 66235,66236 |
| Direct Coombs test | CMBS | 65027,65028 |
| Disopyramide (Rythmodan) | DISO | 66235,66236 |
| Doxepin | DOXE | 66235,66236 |
| Drug abuse treatment programme assay therapeutic - | | |
| DRGA | 66233,66234 |
| (drugs not listed must be written in full) | | (see each drug) |
| or Chemical Assays - Overdose | DRGO | 66231,66232 |
| Electron microscopy of biopsy material | EM | 72807,72808 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Electrophoresis, to demonstrate | | |
| - protein classes, or paraprotein | EPP1 | 66245,66246 |
| - protein classes or presence and amount of paraprotein classes, concurrent collection | EPP2 | 66247,66248 |
| Elements (see individual elements) | | |
| Enzyme assays of solid tissue or tissues | ENZS | 66285,66286 |
| Erythrocyte assessment of Haemolysis | ERYH | 65009,65010 |
| assessment of Metabolic Enzymes | ERYM | 65009,65010 |
| count | RCC | 65001,65002 |
| sedimentation rate | ESR | 65001,65002 |
| Ethosuximide (Zarontin) | ETHO | 66235,66236 |
| Euglobulin clot lysis time | ECLT | 65037,65038 |
| Factor II | FII | 65045,65046 |
| V | FV | 65045,65046 |
| VII | FVII | 65045,65046 |
| VIII | VIII | 65045,65046 |
| IX | FIX | 65045,65046 |
| X | FX | 65045,65046 |
| XI | FXI | 65045,65046 |
| XII | FXII | 65045,65046 |
| XIII | XIII | 65045,65046 |
| XIII deficiency test | F13D | 65029,65030 |
| Faecal Fat | FFAT | 66283,66284 |
| Haemoglobin (chemical test) | FHC | 66217,66218 |
| Haemoglobin (immunological test) | FHI | 66219,66220 |
| Porphyrins (qualitative test) | FPR | 66217,66218 |
| Reducing Substances | FRS | 66217,66218 |
| Ferritin (see also Iron Studies) | FERR | 66251,66252 |
| Fibrin Monomer | FM | 65029,65030 |
| Fibrinogen | FIB | 65029,65030 |
| Degradation Products | FDP | 65029,65030 |
| Fitzgerald Factor | FGF | 65045,65046 |
| Flecainide | FLEC | 66235,66236 |
| Fletcher Factor | FF | 65045,65046 |
| Follicular Stimulating Hormone | FSH | 66301,66302 |
| Fructosamine | FRUC | 66201,66202 |
| Full Blood Examination | FBE | 65007,65008 |
| Gamma Glutamyl Transpeptidase | GGT | 66201,66202 |
| Gastrin | GAST | 66301,66302 |
| Globulin | GLOB | 66201,66202 |
| Glucagon | GSTC | 66297,66298 |
| Glucagon | GLGO | 66301,66302 |
| Glucose | GLUC | 66201,66202 |
| Tolerance Test | GTT | 66201,66202 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Glycosylated Haemoglobin (Hb Ale) | GHB | 66319,66320 |
| Gold | AU | 66277,66278 |
| Gonadotrophin | GRHS | 66297,66298 |
| Growth Hormone | GH | 66301,66302 |
| Hormone-exercise | GHSE | 66295,66296 |
| Hormone-glucose | GHSG | 66295,66296 |
| Haematocrit | HCT | 65001,65002 |
| Haemoglobin Estimation | HB | 65001,65002 |
| Haemoglobinopathy tests | HMGP | 65011,65012 |
| Haptoglobins | HGLB | 66251,66252 |
| HDL Cholesterol | HDLC | 66317,66318 |
| Heparin Cofactor II | HRNC | 65037,65038 |
| Estimation | HEPR | 65043,65044 |
| Hepatitis Serology | | |
| Acute hepatitis | HEP | 69247,69248 |
| Follow-up of proven Hepatitis B | HEPB | 69249,69250 |
| Hepatitis B Serology to define immune status | HEPI | 69245,69246 |
| Hepatitis B surface Antigen HBsAg | HBSA | 69243,69244 |
| Herpes simplex Virus Investigation | | |
| by Cultural Methods | HSVC | 69225,69226 |
| Heterophile Antibodies | IM | 65027,65028 |
| HIAA (Hydroxyindoleacetic acid) | HIAA | 66273,66274 |
| Histamine | HIAM | 66273,66274 |
| Histopathology of biopsy material | HIST | 72801,72802 |
| HLA Typing, comprimising A,B,C and DR phenotypes | HLA | 71051,71052 |
| Typing, one or more antigens | HLAN | 71053,71054 |
| HMMA (Hydroxy Methoxy Mandelic acid -previously known as VMA) | HMMA | 66281,66282 |
| Homovanillic acid | HVA | 66281,66282 |
| Hormone Receptor Assay | HRA | 66315,66316 |
| Ovarian | HRO | 66315,66316 |
| Hormones: | | |
| Adrenocorticotrophic hormone | ACTH | 66301,66302 |
| Aldosterone | ALDS | 66301,66302 |
| Androstenedione | ANDR | 66301,66302 |
| C-Peptide | CPEP | 66301,66302 |
| Calcitonin | CALT | 66301,66302 |
| Cortisol | CORT | 66301,66302 |
| Cyclic AMP | CAMP | 66301,66302 |
| Dehydroepiandrosterone sulphate | DHEA | 66301,66302 |
| Dihydrotestosterone | DHTS | 66301,66302 |
| Follicular Stimulating Hormone | FSH | 66301,66302 |
| Gastrin | GAST | 66301,66302 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Glucagon | GSTC | 66297,66298 |
| Glucagon | GLGO | 66301,66302 |
| Gonadotrophin | GRHS | 66297,66298 |
| Growth Hormone | GH | 66301,66302 |
| Growth Hormone-exercise | GHSE | 66297,66298 |
| Growth Hormone-glucose | GHSG | 66297,66298 |
| Hormone Receptor Assay | HRA | 66315,66316 |
| Human Placental Lactogen | HPL | 66301,66302 |
| Hydroxyprogesterone | OHP | 66301,66302 |
| Insulin | INS | 66301,66302 |
| Insulin | INHY | 66297,66298 |
| Luteinizing Hormone | LH | 66301,66302 |
| Oestradiol | E2 | 66301,66302 |
| Oestriol | E3 | 66301,66302 |
| Oestrone | E1 | 66301,66302 |
| Parathyroid Hormone | PTH | 66301,66302 |
| Pentagastrin | PSTR | 66297,66298 |
| Progesterone | PROG | 66301,66302 |
| Prolactin | PROL | 66301,66302 |
| Renin | REN | 66301,66302 |
| Sex Hormone Binding globulin | SHBG | 66301,66302 |
| Somatomedin | SOMA | 66301,66302 |
| Testosterone | TES | 66301,66302 |
| Thyroid stimulating hormone (where not requested as part of TFTs) | TSH | 66301,66302 |
| Urine Steroid Fraction or Fractions | USF | 66301,66302 |
| Vasoactive Intestinal Peptide | VIP | 66301,66302 |
| Vasopressin | ADH | 66301,66302 |
| 11 Deoxycortisol | DCOR | 66301,66302 |
| Huhner’s test | HT | 73521,73522 |
| Human placental lactogen | HPL | 66301,66302 |
| HVA (Homovanillic acid) | HVA | 66281,66282 |
| Hydroxproline | HYDP | 66273,66274 |
| Hydroxy Methoxy Mandelic acid | | |
| (previously known as VMA) | HMMA | 66281,66282 |
| Hydroxychloriquine | HOCQ | 66235,66236 |
| Hydroxyindoleacetic acid | HIAA | 66273,66274 |
| Hydroxyprogesterone | OHP | 66301,66302 |
| Imipramine | IMIP | 66235,66236 |
| Immediate frozen section diagnosis of biopsy material | FS | 72803,72804 |
| Immunoglobulins £ | IGE | 71013,71014 |
| G, A, M or D | IG | 71005,71006 |
| G, Subclasses 1-4 | SIGG | 71011,71012 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Immunohistochemical investigation of biopsy material | IHIS | 72805,72806 |
| Insulin | INHY | 66297,66298 |
| Insulin | INS | 66301,66302 |
| Intestinal disaccharidases | INTD | 66285,66286 |
| Iron | (see Iron Studies) |
| Iron Studies (Iron, Transferrin and Ferritin) | IS | 66263,66264 |
| L-DOPA | GHLD | 66295,66296 |
| Lactate | LACT | 66273,66274 |
| Dehydrogenase | LDH | 66201,66202 |
| Dehydrogenase Isoenzymes | LDI | 66245,66246 |
| Lamellar body phospholipid | LBPH | 66243,66244 |
| Lead | PB | 66279,66280 |
| Lecithin/Sphingomyelin Ratio (Amniotic fluid) | LS | 66243,66244 |
| Leucocyte Count | WCC | 65001,65002 |
| Fractionation | LF | 71043,71044 |
| Functional tests | LFF | 71045,71046 |
| Surface markers in investigation of probable haematological malignancy | LSMH | 71049,71050 |
| Surface Markers to assess lymphoid populations | LSML | 71047,71048 |
| Lignocaine | LIGN | 66235,66236 |
| Lipase | LIP | 66201,66202 |
| Lithium | LI | 66201,66202 |
| Lupus Anticoagulant | LUPA | 65037,65038 |
| Luteinizing Hormone | LH | 66301,66302 |
| Magnesium | MG | 66201,66202 |
| Mammary serum antigen | MSA | 66251,66252 |
| Manganese | MN | 66277,66278 |
| Mantoux Test | MANT | 71055,71056 |
| Melanogen (see Urine Melanin) | UML | 66213,66214 |
| Mercury | HG | 66277,66278 |
| Metalbumin detection (Schumm’s test) | SCHM | 65027,65028 |
| Metanephrines | MNEP | 66281,66282 |
| Methadone | MTDN | 66235,66236 |
| Methotrexate | MTTA | 66235,66236 |
| Methoxy Hydroxy Phenyethylene Glycol | MHPG | 66281,66282 |
| Methsuximide | MSUX | 66235,66236 |
| Metronidazole | MRDZ | 66235,66236 |
| Mexiletine (Mexitil) | MEX | 66235,66236 |
| MHPG (Methoxy Hydroxy Phenyethylene Glycol) | MHPG | 66281,66282 |
| Microalbumin | MALB | 66251,66252 |
| Microbacteria Microscopy and culture of Sputum | AFB | 69213,69214 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Microbial Antibody Testing | | |
| Actinomycetes | ACT | 69229,69230 |
| Adenovirus | ADE | 69229,69230 |
| Aspergillus | ASP | 69229,69230 |
| Avian precipitins (Bird Fancier’s Disease) | APP | 69229,69230 |
| Blastomyces | BLM | 69229,69230 |
| Bordetella pertussis | BOR | 69229,69230 |
| Borrelia berghoffer | BOB | 69229,69230 |
| Brucella | BRU | 69229,69230 |
| Campylobacter jejuni | CAM | 69229,69230 |
| Candida | CAN | 69229,69230 |
| Chlamydia | CHL | 69229,69230 |
| Coccidioides | CCC | 69229,69230 |
| Coxsackie Bl-6 | COX | 69229,69230 |
| Cryptococcus | CRY | 69229,69230 |
| Cytomegalovirus | CMV | 69229,69230 |
| Cytomegalovirus serology in pregnancy | CMVP | 69227,69228 |
| Dengue | DEN | 69229,69230 |
| Diptheria | DIP | 69229,69230 |
| Echinococcus | ECC | 69229,69230 |
| Echo-coxsakie group | ECH | 69229,69230 |
| Entamoeba Histolytica | AMO | 69229,69230 |
| Epstein Barr Virus | EBV | 69229,69230 |
| Fluorescent Treponemal antibody | | |
| - absorption test (FTA-ABS) | FTA | 69229,69230 |
| Haemophilus | HUS | 69229,69230 |
| Hepatitis delta antibody - Anti-delta | HDA | 69229,69230 |
| Histoplasma | HIP | 69229,69230 |
| Hydatid | HYD | 69229,69230 |
| Influenza A | FLA | 69229,69230 |
| Influenza B | FLB | 69229,69230 |
| Legionella pneumophila - Serogroup 1 | LP1 | 69229,69230 |
| Legionella pneumophila - Serogroup 2 | LP2 | 69229,69230 |
| Leishmaniasis | LEI | 69229,69230 |
| Leptospira | LEP | 69229,69230 |
| Listeria | LIS | 69229,69230 |
| Measles | MEA | 69229,69230 |
| Micropolyspora faeni | MIC | 69229,69230 |
| Mumps | MUM | 69229,69230 |
| Murray Valley Encephalitis | MVE | 69229,69230 |
| Mycoplasma pneumoniae | MYC | 69229,69230 |
| Neisseria gonorrhoea | GON | 69229,69230 |
| Newcastle Disease | NCD | 69229,69230 |
| Parainfluenza 1 | PF1 | 69229,69230 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Parainfluenza 2 | PF2 | 69229,69230 |
| Parainfluenza 3 | PF3 | 69229,69230 |
| Paratyphi | PTY | 69229,69230 |
| Pertussis | PER | 69229,69230 |
| Pneumococcus | PCC | 69229,69230 |
| Poliomyelitis | PLO | 69229,69230 |
| Proteus OX 19 | POX | 69229,69230 |
| Proteus OXK | POK | 69229,69230 |
| Q fever | QFF | 69229,69230 |
| Rapid Plasma Reagin test | RPR | 69229,69230 |
| Respiratory Syncytial Virus | RSV | 69229,69230 |
| Ross River Virus | RRV | 69229,69230 |
| Rubella | RUB | 69229,69230 |
| Rubella Serology in Pregnancy | MSP | 69227,69228 |
| Salmonella typhi (H) | SAH | 69229,69230 |
| Salmonella typhi (0) | SAO | 69229,69230 |
| Schistosoma | STO | 69229,69230 |
| Streptococcal Serology - Anti-D-NASE B titre | ADNB | 69229,69230 |
| Streptococcal Serology-Anti-streptolysin O titre | ASOT | 69229,69230 |
| Tetanus | TET | 69229,69230 |
| Thermoactinomyces vulgaris | THE | 69229,69230 |
| Thermopolyspora | TPS | 69229,69230 |
| Toxocara | TOC | 69229,69230 |
| Toxoplasma | TOX | 69229,69230 |
| Toxoplasma serology in pregnancy | TOXP | 69227,69228 |
| TPHA (Treponema pallidum haemagglutin test) | TPHA | 69229,69230 |
| Treponema pallidum haemagglutin test | TPHA | 69229,69230 |
| Trichonosis | TOS | 69229,69230 |
| Typhus, Weil-Felix | TYP | 69229,69230 |
| Varicella zoster | VCZ | 69229,69230 |
| VDRL (Venereal Disease Research Laboratory) | VDRL | 69229,69230 |
| Yersinia enterocolytica | YER | 69229,69230 |
| Microbial Antigen Testing | | |
| Chlamydia | CHLY | 69221,69222 |
| Herpes simplex Virus | HSV | 69223,69224 |
| Varicella Zoster | VCZN | 69219,69220 |
| Micropolyspora faeni | MIC | 69229,69230 |
| Microscopic examination of faeces for parasites | OCP | 69203,69204 |
| examination of material other than blood | M | 69201,69202 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Microscopy and culture of | | |
| - material from nose, throat, eye or ear | MCS1 | 69205,69206 |
| - material from skin, superficial sites, urethra, vagina, cervix or rectum | MCS2 | 69207,69208 |
| - post-op wounds, aspirations of body cavities, synovial fluid, CSF, op/biopsy specimens | MCS3 | 69209,69210 |
| - specimens of sputum | MCS2 | 69207,69208 |
| - specimens of sputum, urine or other body fluids for mycobacteria | AFB | 69213,69214 |
| Mucin like carcinoma associated antigen | MCA | 66251,66252 |
| N-Acetyl Procainamide | NAPC | 66235,66236 |
| N-Desalkyldothiepin | NDOT | 66235,66236 |
| N-Desalkyl Clobazam | NDAC | 66235,66236 |
| Doxepin | NDAD | 66235,66236 |
| Neuron specific enolase | NSEN | 66251,66252 |
| Nickel | NI | 66277,66278 |
| Nitrazepam | NITR | 66235,66236 |
| Nordothiepin | NDIP | 66235,66236 |
| Nortriptyline | NORT | 66235,66236 |
| Oestradiol | E2 | 66301,66302 |
| Oestriol | E3 | 66301,66302 |
| Oestrone | E1 | 66301,66302 |
| Osmolality, Serum or Urine | OSML | 66223,66224 |
| Oxalate | OXAL | 66273,66274 |
| Oxazepam | OXAZ | 66235,66236 |
| PAA (Phenyl Acetic Acid) | PAA | 66281,66282 |
| Palmitic acid in amniotic fluid | PALM | 66243,66244 |
| Paracetamol | PARA | 66235,66236 |
| Paraprotein Investigation by | | |
| - immuno-electrophoresis or immunofixation | PPRO | 71001,71002 |
| - on concurrently collected serum or urine | PPSU | 71003,71004 |
| Paraquat | PARQ | 66235,66236 |
| Parathyroid Hormone | PTH | 66301,66302 |
| Partial Thromboplastin Time | PTT | 65029,65030 |
| Passovy Factor | PF | 65045,65046 |
| Pentabarb | PENT | 66235,66236 |
| Pentagastrin | PSTR | 66297,66298 |
| Perhexiline | PHEX | 66235,66236 |
| pH measurement of body fluids other man urine | PH | 66213,66214 |
| Phenobarbitone | PHBA | 66235,66236 |
| Phensuximide | PHEN | 66235,66236 |
| Phenyl Acetic Acid | PAA | 66281,66282 |
| Phenytoin | PHEY | 66235,66236 |
Approved item name of test in Schedule | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Porphyrins (quantitative test, one or more fractions) | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Prostate specific antigen | | |
Prostatic Acid Phosphatase | | |
| | | |
| | | |
| | | |
Quantitative estim. of specific protein | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
- Ferritin (see also Iron Studies) | | |
| | | |
| | | |
- Transferrin (see also Iron Studies) | | |
| | | |
| | | |
| | | |
| | | |
| | | |
Red Cell Folate and Serum B12 and Serum Folat if required | | |
| | |
Cell Porphyrins - qualitative test | | |
| | | |
Respiratory Syncytial Virus | | |
| | | |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Rheumatoid Factor | RF | 71033,71034 |
| Factor Quantitation | RFQ | 71035,71036 |
| RSV - Respiratory Syncytial Virus | RSVN | 69219,69220 |
| Salicylate-Aspirin | SALI | 66235,66236 |
| Secretin | SSGR | 66297,66298 |
| Selenium | SE | 66277,66278 |
| Semen examination | SEE | 73523,73524 |
| examination for spermatozoa | SES | 73521,73522 |
| Serotonin | 5HT | 66273,66274 |
| Serum B12 | B12 | 66265,66266 |
| Folate (with B12) | FOL | 66265,66266 |
| Folate (with B12 Red Cell Folate) | RCF | 66267,66268 |
| Sex Hormone Binding globulin | SHBG | 66301,66302 |
| Snake venom | HISS | 66231,66232 |
| Sodium | NA | 66201,66202 |
| Somatomedin | SOMA | 66301,66302 |
| Sotalol | SALL | 66235,66236 |
| Specific IgG or IgE antibodies | ALLG | 71015,71016 |
| Sperm antibodies | SAB | 73525,73526 |
| penetrating ability | SPA | 73525,73526 |
| Stellazine | STEL | 66235,66236 |
| Strontium | SR | 66277,66278 |
| Sulphadimidine | SPDD | 66235,66236 |
| Sulthiame (Ospolot) | SUL | 66235,66236 |
| Synacthen Stimulation Test | SYNS | 66301,66302 |
| Testosterone | TES | 66301,66302 |
| Thalassaemia Studies | TS | 65011,65012 |
| Theophylline | THEO | 66235,66236 |
| Therapeutic Drugs not listed must be written in full | | ---- |
| Thiopentone | TOPO | 66235,66236 |
| Thioridazine | THIO | 66235,66236 |
| Thrombin Time | TT | 65029,65030 |
| Thyroglobulin | TGL | 66251,66252 |
| Thyroid function tests | TFT | 66291,66292 |
| stimulating hormone | TSH | 66301,66302 |
| stimulating hormone (where not requested as part of TSTs) | TSH | 66301,66302 |
| Thyrotrophin Releasing Hormone Test | TRH | 66293,66294 |
| Tissue antigens which are not listed must be written in full | | ---- |
| Tocainide | TOCN | 66235,66236 |
| Total free fatty acids | TFFA | 66273,66274 |
| Approved item name of test in Schedule | Abbreviation | Item Number |
| Transferrin (see also Iron Studies) | TRAN | 66251,66252 |
| Triglycerides | TRIG | 66201,66202 |
| Trimipramine | TRIM | 66235,66236 |
| TSH (where not requested as part of a thyroid function test) | TSH | 66301,66302 |
| Tumour Markers | | |
| CA-125 antigen | C125 | 66251,66252 |
| CA-19.9 antigen | CA19 | 66251,66252 |
| CA-15.3 antigen | CA15 | 66251,66252 |
| Carcinoembryonic antigen | CEA | 66251,66252 |
| Hormone receptor ovarian | HRO | 66315,66316 |
| Mammary serum antigen | MSA | 66251,66252 |
| Mucin like carcinoma associated antigen | MCA | 66251,66252 |
| Neuron specific enolase | NSEN | 66251,66252 |
| Prostate specific antigen | PSA | 66251,66252 |
| Prostatic Acid Phosphatase-one or more fractions | ACP | 66251,66252 |
| Thyroglobulin | TGL | 66251,66252 |
| Urate | URAT | 66201,66202 |
| Urea | U | 66201,66202 |
| Urine Bilirubin | UBIL | 66213,66214 |
| Cysteine (see Urine Cystine) | UCYS | 66213,66214 |
| Cystine (Cysteine) | UCYS | 66213,66214 |
| Haemoglobin | UHB | 66213,66214 |
| Melanin (Melanogen) | UML | 66213,66214 |
| |